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Long-term Outcome of Cardiovascular Prevention:
A Nijmegen Academic Family Practices Network
Study
Chris van Weel, MD, PhD, Carel Bakx, MD, PhD, Henk van den Hoogen,
Theo Thien, MD, PhD, and Wil van den Bosch, MD, PhD
Context: Cardiovascular disease is common and preventable. Primary care is the preferred setting for
individual prevention and management.
Objective: This study analyzed the long-term outcome of cardiovascular risk in a family practice pop-
ulation.
Design: A longitudinal cohort analysis of cardiovascular outcome after 18 years, in participants of a
randomized controlled trial (RCT) of cardiovascular prevention. In 1977, a RCT with cluster random-
ization at practice level assessed the effects of a 1-year preventive intervention in patients 20 to 50
years of age. Cardiovascular risk factors (smoking, body mass index, blood pressure, serum choles-
terol, family history, and physical activity) were measured and intervention was a practice-nurse sup-
port for the follow-up of those at elevated risk. The control practices prescribed care as usual. Between
1994 and 1995, all participants were approached again, to analyze subsequent (cardiovascular) mortal-
ity and morbidity and their cardiovascular risk in a random sample.
Setting: The Nijmegen Academic Family Practices Network, The Netherlands.
Participants: All participants (7092) of the 1977 screening for follow-up morbidity and mortality,
2600 for re-measurement risk factors.
Outcome measures: Cardiovascular risk factors; cardiovascular morbidity and mortality 1977–1995.
Results: Follow-up was achieved in 5945 participants (84%) and 2335 participated in the re-mea-
surement (89%). No effects of the preventive intervention were found, but those initially at low risk
profile were still so 18 years later. Risk of subsequent cardiovascular mortality and morbidity was re-
lated to baseline risk, but for women, the absolute risk was low in all risk strata and lower than pre-
dicted from international references.
Conclusions: This study demonstrated the feasibility of family practice network research in pursuing
longitudinal research. A single cardiovascular screening resulted in reliable risk assessment: those ini-
tially at low risk still were so after 18 years. Effects of a 1-year intensive intervention could no longer
be demonstrated. (J Am Board Fam Med 2006;19:62–8.)
Ischemic cardiovascular diseases belong to the most
common chronic disorders in the primary care
population contributing substantially to the work-
load of family practice.1,2 Co-morbidity is a fre-
quent feature of patients with ischemic heart dis-
ease,1,3 caused by common causal mechanisms (for
example diabetes mellitus or smoking-related
chronic obstructive pulmonary disease) and/or as
the consequence of ageing. This hampers the ef-
fectiveness of treatment, and because cardiovascu-
lar disease is preventable, underlines the case of
prevention. Effective cardiovascular prevention
should be directed at persons at elevated risk4 and
involves case-ﬁnding through the assessment of risk
factors (smoking, obesity, diabetes mellitus, hyper-
tension, hyperlipidemia, family history of ischemic
heart disease).5 Primary care is the preferred setting
for individual prevention and management but
family physicians (FP) ﬁnd it difﬁcult to relate their
efforts to established health gains of their patients:
postponement of events or death cannot be measured
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on an individual level, and care is directed at inter-
mediate targets (smoking cessation, weight-loss,
and control of diabetes, blood pressure, and serum
lipids). There is substantial evidence of the prob-
lems to achieve lasting control over these interme-
diate targets in itself,6,7 but there is also limited
insight in the actual impact of cardiovascular pre-
vention in family practice. For that reason, we fol-
lowed-up a cohort that had been recruited by their
FP for individual cardiovascular prevention, 18
years before. The aim of this study was to assess the
long-term outcome of cardiovascular risk in a fam-
ily practice population and their population-spe-
ciﬁc risks. Based on the experiences, a practice
audit-and-support for cardiovascular prevention
was developed.
Methods
The study was a longitudinal cohort analysis of
cardiovascular outcome of participants of a ran-
domized controlled trial of cardiovascular preven-
tion after 18 years. Participating practices formed
the Nijmegen academic family practices network,
the practice-based research network of the Depart-
ment of Family Medicine Nijmegen (The Nether-
lands). This network records all episodes of pre-
sented morbidity since 1971 in a standardized way,
and the process and outcome of a number of
chronic diseases (diabetes mellitus, hypertension,
asthma/chronic obstructive pulmonary disease)
since 1986.8–10
The 1977 study was a randomized clinical trial
of the feasibility and the effects of intervention on
cardiovascular risk factors in family practice con-
ducted between February 1977 to September
1978.11 The intervention consisted of practice sup-
port for preventive cardiovascular care: After clus-
ter randomization at practice level 3 practices re-
ceived support of a practice-nurse for the follow-up
and management of patients at elevated cardiovas-
cular risk. The 3 control practices prescribed care
as usual. The intervention lasted for a year.
Participants and Measurements
All patients, born between 1927 and 1957, were
invited in for a health screening, when they visited
their physician. Assessment of cardiovascular risk
factors was done with the help of specially trained
assistants. A 33% sample of those who had not
come to the practice in that period was invited by
letter. This resulted in the measurement of cardio-
vascular risk factors in 7092 persons. A question-
naire about family risk factors, smoking habits, and
physical activity was administered. Blood pressure,
height, and body weight were assessed, and a blood
sample was taken for serum cholesterol. Blood
pressure was taken as the average of 2 readings,
measured twice in the right arm of sitting subjects
after a 5-minute rest. The ﬁfth phase of the Korot-
koff sounds was recorded as the diastolic blood
pressure. For subjects with an arm circumference of
less than 30 cm, a bladder of 13  23 cm was used,
and for obese subjects, a bladder of 16  23 cm.
Non-fasting serum cholesterol concentration
was measured with the Liebermann-Burchard re-
agent with Huang modiﬁcation at the Laboratory
of the Wageningen Agriculture University. The
laboratory participated in the “Cooperative Cho-
lesterol Standardization Program” of the World
Health Organization, with the Center for Research
in Blood Lipids in Atlanta as reference.12
Socioeconomic class was based on the profession
of the participants and divided in 3 categories, up-
per, middle, and lower.
A cardiovascular risk proﬁle was drawn up for
every patient, and the 20% with the highest risk
level, the so-called high-risk group, were referred
to their FP. The cardiovascular risk allocation was
based on BP, smoking habits, serum cholesterol,
the existence of diabetes, and family history for
cardiovascular disease. Criteria for the high-risk
proﬁle were derived from the Coronary Risk
Handbook from the American Heart Association,13
without the criteria for electrocardiogram abnor-
malities
Follow-up Study: Health Status Outcome
1978–1995
Participants
As a ﬁrst step, it was established whether partici-
pants of the screening were still alive and lived in
the practice area. The ﬁles of the deceased patients
were studied for the cause of death. Of those who
had moved to another area, their new FP was con-
tacted to establish their current health status. The
subjects still living in the practice area were con-
sidered for the follow-up study 5945 of cardiovas-
cular morbidity. All patients who had an elevated
cardiovascular risk during the 1977 screening, as
well as a random sample of 33% of those with a
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low-normal cardiovascular risk at that time were
invited. A total of 2600 patients were invited for
re-measurement of the cardiovascular risk factors.
Mortality and Cardiovascular Morbidity
Mortality and cause of death (myocardial infarc-
tion, sudden death, heart failure, stroke) and car-
diovascular morbidity between 1977 and 1995 were
recorded according to the ICHPPC-2-deﬁned cri-
teria14 in the Nijmegen morbidity registration.8–10
For this study, the ﬁrst onset of angina pectoris,
myocardial infarction, and stroke were recruited
from the registration as the outcome variable for
CVD morbidity.
Cardiovascular Risk Status
Cardiovascular risk status in 1995 was assessed dur-
ing a re-screening, with the help of specially trained
assistants. The assistants who measured in 1995
were blinded to the 1977 ﬁndings. For blood pres-
sure measurement, a bladder of 13  36 cm was
used for every one, according to the present guide-
lines of the Dutch College of General Practitio-
ners.15
The non-fasting serum cholesterol was mea-
sured in the Canisius Wilhelmina Hospital in Ni-
jmegen with an enzymatic cholesterol assay method
(Technicon method). The quality control data
were analyzed to detect laboratory drifts that could
inﬂuence the results. The Canisius Wilhelmina
Hospital, as a member of the Dutch Foundation of
Clinical Chemical Laboratories, meets WHO qual-
ity control standards. Because of the careful stan-
dardization following WHO quality control stan-
dards, it can be assumed that cholesterol values
from 1977 and 1995 are comparable.
Body weight was measured, and smoking status
and familial risk factors were also administered.
Family history of cardiovascular disease was an
ischemic cardiovascular event (angina, myocardial
infarction, stroke, transient ischemic attack, or pe-
ripheral arterial obstruction) and/or sudden death
in a ﬁrst-degree relative before the age of 65 year.
Respondents were classiﬁed as current smokers,
never smokers, and earlier smokers.16–18
Analysis
Normal blood pressure was deﬁned as a systolic
blood pressure of 140 mm Hg and a diastolic
blood pressure of 90 mm Hg. The high blood
pressure group included those currently using an-
tihypertensive medication. The deﬁnition of ele-
vated serum total cholesterol was a measurement of
5.8 mmol/L and the deﬁnition of overweight was
a body mass index measurement of27 kg/m2. For
smoking “past” or “never” were grouped together
versus “current”. For analysis of family history, all
patients reporting an event in one or more relatives
were considered a positive family history, all others
a negative one. As no lasting effects of the preven-
tive intervention had been found11,19–21 patients of
intervention practices and control practices were
combined in this analysis. Cox proportional hazard
regression was used with cardiovascular risk status
at screening in 1977 to 1978 as the independent
variable and the onset of a ﬁrst cardiovascular dis-
ease event as the (dependent) outcome variable.
Hazard ratios for separate and combined risk fac-
tors and relative risks were estimated. As cardiovas-
cular events were rare in patients 20–30 years at
screening in 1977, formal risk calculation has been




In preparing the follow-up measurement differ-
ences in medical routines between 1977 and 1995
were identiﬁed, but without empirical evidence
of their implications. This was in particular the
case of the use of cuffs in blood pressure readings
–for 1977: in subjects with an arm circumference
of less than 30 cm, a bladder of 13  23 cm was
used,11 and in obese subjects a bladder of 16  23
cm., for 1995: a 13  36 cm bladder size was
recommended irrespective of arm circumfer-
ence.15 In a comparative study in subjects with
different arm circumference, blood pressure
readings with cuffs of 13  23 cm. and 13  36
cm. were taken. In comparing the measurement
outcomes, differences were marginal and within
the measurement variation,22 which supported
the decision to use a 13  36 cm bladder size for
everyone in the 1995 study.16–18
Longitudinal Analysis
In 1977, 7092 patients participated in the study, of
which 1147 had left the practice (area) in 1995. A
total of 205 patients had died before 1995, of whom
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54 from cardiovascular causes (45 sudden death or
myocardial infarction, 9 stroke). Further follow-up
was directed at those alive in 1995 (5945 or 84%).
There had been 268 cases of non-fatal angina pec-
toris or myocardial infarction and 69 cases of
stroke, transient ischemic attack recorded between
1977 and 1995.
The number of smokers decreased approxi-
mately 50% from 63% in 1977 to 35% in 1995 for
men (this was 45% and 27%, respectively, for
women). Average blood pressure did not increase
signiﬁcantly over the years, but serum cholesterol
did, for men and women (Table 1). The number of
patients with a blood pressure or cholesterol above
the cutoff point, however, did increase (Table 1).
For blood pressure, this was partially because of
changes in the cutoff point: when the 1995 criteria
for hypertension were applied for the situation
1977, 9.5% of the men and 6.5% of the women
would have been categorized as hypertensive.16
Those initially classiﬁed as low-normal blood
pressure were for approximately 90% so at follow-
up, whereas 65% of patients whose blood pressure
had initially been classiﬁed as elevated, were still so
18 years later (Figure 1). Table 2 summarizes the
relative risk of subsequent cardiovascular mortality
and morbidity in relation to baseline risk. All risk
factors, and in particular hypercholesterol, were
related to cardiovascular morbidity and mortality.
The absolute risk of a life-time ﬁrst myocardial
infarction was 3.7 per 1000 for men and 2.7 per
1000 for women.
Table 1. Development of Blood Pressure and Cholesterol 1977–1995 and Percentage of Categorized Hypertensive,
Hypercholestrolemia
Men Women
1977 1995 1977 1995
Blood pressure
Systolic 135 (13.3) 135 (16.4) 128 (14.0) 132 (18.7)
Diastolic 81 (10.0) 84 (9.2) 80 (9.8) 82 (9.2)
Hypertensive (%) 9.5 13.5 6.5 16.4
Cholesterol 5.5 (1.1) 6.2 (1.1) 5.2 (1.0) 6.1 (1.1)
Hypercholestolemia (%) 28 41 18 38




This study assessed in a family practice population
the development of blood pressure and serum cho-
lesterol over a period of 18 years and the cardio-
vascular morbidity and mortality over that period
in relation to cardiovascular risk. It demonstrated
that a baseline assessment of blood pressure, and to
a lesser degree serum cholesterol, correlated well
with the patients’ values nearly 2 decades later.
This supports the view that a “one-off” screening
of these risk factors allows for long-term risk allo-
cation.23 This is important as biological and mea-
surement variation inﬂuence measurement. Al-
though for serum cholesterol, there was a clear
increase over time for men and women. Changing
population nutrition24 and ageing of the study
group might be responsible for this. The yield of
hypertension in 1977 would have been much
higher, when the prevailing criteria of 1995 were
applied.
This may illustrate the effects of changing diag-
nostic criteria over time, that is an inherent factor
in longitudinal research. During the follow-up, the
treatment targets became gradually tighter, partic-
ularly for hypertension (140/90 mm Hg)15 and
cholesterol ( 5.0 mmol/L)25 and more and more
drugs became available. The Nijmegen academic
practice-based research network in which the prac-
tices participate has over the years adopted these
targets and monitored their achievement.10 Out-
come of cardiovascular risk in this study reﬂects the
continuous changing potential of care.
This should be taken into account in revisiting
the question of why an initially successful interven-
tion petered-out. Usual explanations are patient
and physician compliance and the stripping-down
of the research setting. In this study the departure
of the study nurse practitioners will have had a
tangible effect. But although there is no reason to
expect these practices to be exempt from such in-
ﬂuences, it is also quite likely that changes in the
control practices have inﬂuenced the results. Pro-
active care for cardiovascular risk has been pro-
moted in (Dutch) family practice, for example in
the Dutch college’s guidelines for hypertension15
and cholesterol.25 And the Nijmegen academic
practice-based research network has developed its
methods of audit and feed-back to foster its objec-
tives in routine care. That under these circum-
stances the beneﬁts of the intervention can no
longer be identiﬁed, to a large extent, could be
because of improvements in the control practices.
Baseline risk factors were related to subsequent
cardiovascular risk, in line with previous population
risk studies.26–28 But interestingly, the overall de-
gree of risk of this population was lower than of
other populations.
The longitudinal study was superimposed on a
RCT of the effectiveness of cardiovascular preven-
tion and it may be assumed that participants of this
study received treatment of their cardiovascular
risk. This could have inﬂuenced the rate of cardio-
vascular disease and mortality and this would have
led to an underestimation of the actual risk. Smok-
ing cessation would also have caused this. The
decline of smoking in this population was similar to
the secular trend in The Netherlands during the
study period.29 But similar effects must have inﬂu-
enced the risk assessment over time in other pop-
ulations, that are often used as reference values for
the rationale of cardiovascular prevention recom-
mendations, and in the initial study of this popula-
tion no lasting effects of a one-year intensive inter-
vention could be demonstrated.20,21 This would
Table 2. Number of Participants with Elevated Risk Factors in 1977 and Their Relative Risk (95% CI) of
Cardiovascular Events 1977–1995 in the Nijmegen Cohort Study
Men Women
Number
(n  2055) Relative Risk
Number
(n  2152) Relative Risk
Hypercholesterolemia
(total cholesterol 5.8 mmol/L)
794 2.5 (1.9–2.9) 490 1.9 (1.1–3.4)
Hypertension
(systolic blood pressure 140 mm Hg
or under treatment)
340 1.8 (1.2–2.3) 329 1.7 (0.8–2.5)
Smoking (10 cigarettes daily) 944 1.8 (1.2–2.4) 588 1.4 (0.8–2.4)
Obesity (body mass index 27 kg/m2) 436 1.6 (1.2–2.0) 448 1.9 (1.1–2.8)
Family history of cardiovascular disease 371 1.8 (1.3–2.5) 439 1.9 (1.1–3.3)
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still imply that this family practice population had
an overall lower risk of cardiovascular events. This
is relevant knowledge as it might inﬂuence the
cost-effectiveness of prevention in this population.
The risk of a lifetime ﬁrst myocardial infarction
was lower than in the Framingham population—
that is the risk-table evidence on which global car-
diovascular screening is based. This is in line with
other (European) populations30 and emphasizes the
need of population-speciﬁc research. This lower
risk came down even further during the study pe-
riod; we could demonstrate a decline in the inci-
dence of ﬁrst myocardial infarction between 1975
and 2003.31
This emphasizes the importance of studying
populations under care for their own characteristics
of their health status: it is only to a certain degree
possible to generalize ﬁndings from one population
to another. That is also true for the ﬁndings of this
study that took place in an academic family practice
network. The FPs and their care can for that reason
not be generalized. But practices provided care for
unselected groups of patients, living in the commu-
nities the practices serve. As a consequence, the
data for cardiovascular risk in relation to cardiovas-
cular morbidity can be generalized –with all the
caveats stressed above.
A particular point of this study was that it dem-
onstrated the feasibility of a family practice net-
work research in pursuing longitudinal research.
This emphasizes the role of practice-based research
networks to track patients’ careers and morbidity
events of time,9 which can make a powerful contri-
bution to clinical research.
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